Why the study?
Does extended-release exenatide increase [18F]FDG uptake by brown adipose tissue in nondiabetic men without obesity?
Population
24 nondiabetic men without obesity (12 Dutch South Asian and 12 age- and BMI-matched Europid)
Design
Cohort
Follow-up
12 weeks
Key result
Twelve weeks of exenatide treatment increased brown adipose tissue metabolic volume by 28% (p<0.05) and mean standardized uptake value by 11% (p<0.05) in nondiabetic men.
Authors
Loading...
Should not yet change practice; hypothesis-generating for GLP-1 effects on BAT and needs RCT confirmation.
Does extended-release exenatide increase [18F]FDG uptake by brown adipose tissue in nondiabetic men without obesity?
p-value: p=<0.05
GLP-1R agonism with exenatide increases brown adipose tissue metabolic activity in nondiabetic men without obesity, providing a potential mechanism for its metabolic benefits.
Janssen et al. (2020) studied Without obesity or type 2 diabetes (n=24). Extended-release exenatide vs. Baseline was evaluated on Brown adipose tissue (BAT) metabolic volume (p=<0.05). Twelve weeks of exenatide treatment increased brown adipose tissue metabolic volume by 28% (p<0.05) and mean standardized uptake value by 11% (p<0.05) in nondiabetic men.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: